Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 17/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7103188 | 0.86 | EGFR (0.52) | EGFRCSF1RLCKSRCKDR | |
| SCHEMBL3124060 | 0.81 | LCK (0.54) | EGFRCSF1RLCKSRCLIMK1 | |
| SCHEMBL17665717 | 0.76 | CSF1R (0.69) | CSF1R | |
| SCHEMBL17665420 | 0.76 | CSF1R (0.80) | CSF1R | |
| SCHEMBL3108981 | 0.74 | EGFR (0.53) | EGFRCSF1R | |
| SCHEMBL28953972 | 0.72 | EGFR (0.47) | EGFR | |
| SCHEMBL22587605 | 0.68 | NPC1 (0.42) | FAAHMGLL | |
| SCHEMBL9524227 | 0.68 | NPC1 (0.56) | LCKSRCKDRLIMK1LIMK2 | |
| SCHEMBL17665470 | 0.67 | CSF1R (0.65) | CSF1R | |
| SCHEMBL2074490 | 0.66 | SRC (0.61) | EGFRCSF1RLCKSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4707167-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| EP-1496910-A4 | KINASE INHIBITORS | ABBOTT LAB (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1496910-A1 | KINASE INHIBITORS | Abbott Laboratories (US) | 2005-01-19 | — | — | EP | claimed |
| US-20030225098-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | claimed |
| US-20030199525-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | claimed |
| WO-2003080064-A1 | KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | claimed |
| US-7829570-B2 | Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100041676-A1 | Kinase inhibitors | ABBVIE INC. | 2010-02-18 | — | — | US | disclosed |
| US-20030225098-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| US-20030199525-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199525-A1 | Kinase inhibitors | MAP3K19, MAP3K9, MAP3K1 | EGFR 346/4885CSF1R 797/4885LCK 70/4885 |
| US-20030225098-A1 | Kinase inhibitors | MAP3K19, MAP3K9, MAP3K1 | EGFR 298/4885CSF1R 651/4885LCK 91/4885 |
| US-20100041676-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K6 | EGFR 232/4885CSF1R 1208/4885LCK 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.